520MO Safety and efficacy of nivolumab (NIVO) ± ipilimumab (IPI) in patients (pts) with recurrent/metastatic cervical cancer (R/M Cx Ca) in checkmate 358 von Oaknin, A., Moore, K.N., Meyer, T., González, J.L., Devriese, L., Amin, A., Lao, C.D., Boni, V., Sharfman, W.H., Park, J.C., Tahara, M., Topalian, S.L., Magallanes Maciel, M.E., Molina Alavez, A., Khan, A., Copigneaux, C., Lee, M., Garnett-Benson, C., Wang, X., Naumann, R.W.

Volltext

Phase I trial of weekly tigatuzumab, an agonistic humanized monoclonal antibody targeting death receptor 5 (DR5) von Forero-Torres, Andres, Shah, Jatin, Wood, Tina, Posey, James, Carlisle, Ronda, Copigneaux, Catherine, Luo, Feng Roger, Wojtowicz-Praga, Slawomir, Percent, Ivor, Saleh, Mansoor

Volltext

1336TiPPHASE (PH) 3 STUDY OF PATRITUMAB (P) PLUS ERLOTINIB (E) IN EGFR WILD-TYPE SUBJECTS WITH ADVANCED NON–SMALL CELL LUNG CANCER (NSCLC) von Paz-Ares, L., von Pawel, J., Moritz, B., Mendell, J., Jin, X., Copigneaux, C., Beckman, R.

Volltext

Phase (Ph) 3 Study of Patritumab (P) Plus Erlotinib (E) in Egfr Wild-Type Subjects with Advanced Non–Small Cell Lung Cancer (Nsclc) von Paz-Ares, L., von Pawel, J., Moritz, B., Mendell, J., Jin, X., Copigneaux, C., Beckman, R.

Volltext

234 A phase 1, open-label, dose-finding study to assess the safety and tolerability of U3 1287 (AMG 888), a human monoclonal antibody targeting HER3 in patients with advanced solid... von LoRusso, P, Keedy, V, Yee, L, Oliveira, M, Rizvi, N, Berlin, J, Jin, X, Hettmann, T, Copigneaux, C, Beaupre, D

Volltext

Abstract P4-16-09: Phase 1b/2 trial of the HER3 inhibitor patritumab (U3-1287) in combination with trastuzumab plus paclitaxel in newly-diagnosed patients with HER2+ metastatic bre... von Carraro, S, Campos, D, Copigneaux, C, Saintilien, C, Beckman, RA, Korbenfeld, E, Coppola, MP, Halabe, K, Cazap, E

Volltext

A first-in-human phase I study of U3-1287 (AMG 888), a HER3 inhibitor, in patients (pts) with advanced solid tumors von Berlin, J., Keedy, V. L., Janne, P. A., Yee, L., Rizvi, N. A., Jin, X., Copigneaux, C., Hettmann, T., Beaupre, D. M., LoRusso, P.

Volltext

Final reporting of a phase I clinical trial of the oral PPAR-gamma agonist, CS-7017, in patients with advanced malignancies von Pishvaian, M. J., Cotarla, I., Wagner, A. J., Deeken, J. F., He, A. R., Hwang, J. J., Demetri, G. D., Halim, A., Copigneaux, C., Marshall, J.

Volltext

First-in-human study of the antibody DR5 agonist DS-8273a in patients with advanced solid tumors von Forero, Andres, Bendell, Johanna C., Kumar, Prasanna, Janisch, Linda, Rosen, Michael, Wang, Qiang, Copigneaux, Catherine, Desai, Madhuri, Senaldi, Giorgio, Maitland, Michael L.

Volltext

The Next Generation Internet of Things – Hyperconnectivity and Embedded Intelligence at the Edge von Vermesan, Ovidiu, Eisenhauer, Markus, Serrano, Martin, Guillemin, Patrick, Sundmaeker, Harald, Tragos, Elias Z, Valino, Javier, Copigneaux, Bertrand, Presser, Mirko, Aagaard, Annabeth, Bahr, Roy, Darmois, Emmanuel C

Volltext bestellen

The Next Generation Internet of Things - Hyperconnectivity and Embedded Intelligence at the Edge von Vermesan, Ovidiu, Eisenhauer, Markus, Serrano, Martin, Guillemin, Patrick, Sundmaeker, Harald, Tragos, Elias Z., Valiño, Javier, Copigneaux, Bertrand, Presser, Mirko, Aagaard, Annabeth, Bahr, Roy, Darmois, Emmanuel C.

Volltext

The Next Generation Internet of Things – Hyperconnectivity and Embedded Intelligence at the Edge von Vermesan, Ovidiu, Eisenhauer, Markus, Serrano, Martin, Guillemin, Patrick, Sundmaeker, Harald, Tragos, Elias Z., Valino, Javier, Copigneaux, Bertrand, Presser, Mirko, Aagaard, Annabeth, Bahr, Roy, Darmois, Emmanuel C.

Volltext